A review of strategies to overcome immune resistance in the treatment of advanced prostate cancer
- PMID: 37842236
- PMCID: PMC10571060
- DOI: 10.20517/cdr.2023.48
A review of strategies to overcome immune resistance in the treatment of advanced prostate cancer
Abstract
Immunotherapy has become integral in cancer therapeutics over the past two decades and is now part of standard-of-care treatment in multiple cancer types. While various biomarkers and pathway alterations such as dMMR, CDK12, and AR-V7 have been identified in advanced prostate cancer to predict immunotherapy responsiveness, the vast majority of prostate cancer remain intrinsically immune-resistant, as evidenced by low response rates to anti-PD(L)1 monotherapy. Since regulatory approval of the vaccine therapy sipuleucel-T in the biomarker-unselected population, there has not been much success with immunotherapy treatment in advanced prostate cancer. Researchers have looked at various strategies to overcome immune resistance, including the identification of more biomarkers and the combination of immunotherapy with existing effective prostate cancer treatments. On the horizon, novel drugs using bispecific T-cell engager (BiTE) and chimeric antigen receptors (CAR) technology are being explored and have shown promising early efficacy in this disease. Here we discuss the features of the tumour microenvironment that predispose to immune resistance and rational strategies to enhance antitumour responsiveness in advanced prostate cancer.
Keywords: Prostate cancer; immune checkpoint inhibitor; immune resistance; immunotherapy; tumour microenvironment.
© The Author(s) 2023.
Conflict of interest statement
All authors declared that there are no conflicts of interest.
Figures
Similar articles
-
Bispecific PSMA antibodies and CAR-T in metastatic castration-resistant prostate cancer.Ther Adv Urol. 2023 Jun 15;15:17562872231182219. doi: 10.1177/17562872231182219. eCollection 2023 Jan-Dec. Ther Adv Urol. 2023. PMID: 37359737 Free PMC article. Review.
-
Refining Immuno-Oncology Approaches in Metastatic Prostate Cancer: Transcending Current Limitations.Curr Treat Options Oncol. 2021 Jan 12;22(2):13. doi: 10.1007/s11864-020-00808-x. Curr Treat Options Oncol. 2021. PMID: 33433743 Review.
-
Immunotherapy in Advanced Prostate Cancer: Current Knowledge and Future Directions.Biomedicines. 2022 Feb 24;10(3):537. doi: 10.3390/biomedicines10030537. Biomedicines. 2022. PMID: 35327339 Free PMC article. Review.
-
Bispecific T-Cell Engagers Therapies in Solid Tumors: Focusing on Prostate Cancer.Cancers (Basel). 2023 Feb 23;15(5):1412. doi: 10.3390/cancers15051412. Cancers (Basel). 2023. PMID: 36900202 Free PMC article. Review.
-
Immune Checkpoint Inhibitors in Advanced Prostate Cancer: Current Data and Future Perspectives.Cancers (Basel). 2022 Feb 28;14(5):1245. doi: 10.3390/cancers14051245. Cancers (Basel). 2022. PMID: 35267553 Free PMC article. Review.
Cited by
-
Immunogenic cell death signatures from on-treatment tumor specimens predict immune checkpoint therapy response in metastatic melanoma.Sci Rep. 2024 Oct 2;14(1):22872. doi: 10.1038/s41598-024-74636-6. Sci Rep. 2024. PMID: 39358546 Free PMC article.
-
Causal relationship between immune cells and prostate cancer: a Mendelian randomization study.Front Cell Dev Biol. 2024 Mar 19;12:1381920. doi: 10.3389/fcell.2024.1381920. eCollection 2024. Front Cell Dev Biol. 2024. PMID: 38566827 Free PMC article.
References
-
- Cancer stat facts: prostate cancer. Available from: https://seer.cancer.gov/statfacts/html/prost.html . [Last accessed on 19 Sep 2023]
-
- FDA grants accelerated approval to pembrolizumab for first tissue/site agnostic indication. Available from: https://www.fda.gov/drugs/resources-information-approved-drugs/fda-grant... . [Last accessed on 19 Sep 2023]
-
- FDA grants accelerated approval to dostarlimab-gxly for dMMR advanced solid tumors. Available from: https://www.fda.gov/drugs/resources-information-approved-drugs/fda-grant... . [Last accessed on 19 Sep 2023]
Publication types
LinkOut - more resources
Full Text Sources
Research Materials
Miscellaneous